This study aims to see if maintenance treatment with torvu-sam in combination with bevacizumab allows patients to live longer without the cancer getting worse, compared to patients receiving bevacizumab.
Eligible patients will be those with advanced ovarian cancer who have not progressed following completion of first-line platinum-based chemotherapy (PBC) and bevacizumab.